ReviewReviews in endocrine & metabolic disorders2007
SERMs for the treatment and prevention of breast cancer.
Review in Reviews in endocrine & metabolic disorders, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 101 citations in OpenAlex.
- Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene.Clinical interventions in aging · 2008Pooled it
- The effects of tamoxifen and its metabolites on circulating estrogen metabolites among pre- and postmenopausal women.Steroids · 2026Article
- Targeting ESR1 restores SQSTM1-dependent autophagy and sensitizes ER-positive breast cancer to oxidative and radiation stress.Cell death discovery · 2025Article
- Raloxifene Prevents Chemically-Induced Ferroptotic Neuronal Death In Vitro and In Vivo.Molecular neurobiology · 2025Article
- Escalation and De-Escalation Strategies for Endocrine Therapy in Early-Stage Breast Cancer.Biologics : targets & therapy · 2025Review
- Identification of Novel Inhibitors for ERα Target of Breast Cancer By In silico Approach.Current computer-aided drug design · 2025Article
- Article
- Unveiling the Power of Flax Lignans: From Plant Biosynthesis to Human Health Benefits.Nutrients · 2024Review
- Computational Screening of Some Phytochemicals to Identify Best Modulators for Ligand Binding Domain of Estrogen Receptor Alpha.Current pharmaceutical design · 2024Article
- Targeting sex steroid biosynthesis for breast and prostate cancer therapy.Nature reviews. Cancer · 2023Review
- Role of the pharmacist in the management of postmenopausal breast cancer treatment with vasomotor symptoms: A case report.Exploratory research in clinical and social pharmacy · 2023Article
- An Update on Tamoxifen and the Chemo-Preventive Potential of Vitamin E in Breast Cancer Management.Journal of personalized medicine · 2023Review
- Guava Leaf Essential Oil as a Potent Antioxidant and Anticancer Agent: Validated through Experimental and Computational Study.Antioxidants (Basel, Switzerland) · 2022Article
- Tripartite motif-containing 3 (TRIM3) enhances ER signaling and confers tamoxifen resistance in breast cancer.Oncogenesis · 2021Article
- Pharmacological and Therapeutic Properties ofMolecules (Basel, Switzerland) · 2021Review
- Article
- Kinase-substrate Edge Biomarkers Provide a More Accurate Prognostic Prediction in ER-negative Breast Cancer.Genomics, proteomics & bioinformatics · 2020Article
- Naturally-Occurring Canine Mammary Tumors as a Translational Model for Human Breast Cancer.Frontiers in oncology · 2020Review
- Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer.EMBO molecular medicine · 2019Article
- Tamoxifen side effects: pharmacogenetic and clinical approach in Mexican mestizos.Translational cancer research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Tamoxifen and raloxifene are both selective estrogen receptor modulators (SERMs). The medicines can block estrogen mediated breast cancer growth and development but will also maintain bone density in postmenopausal women and lower circulating cholesterol. Tamoxifen has remained the antihormonal therapy of choice for the treatment of ER positive breast cancer for the last 30 years. However, although adjuvant tamoxifen produces profound increases in disease-free and overall survival in patients with ER positive breast cancer, concerns about drug resistance, blood clots and endometrial cancer have resulted in a change to the use of aromatase inhibitors for the treatment of postmenopausal women. Nevertheless, tamoxifen remains the antihormonal treatment of choice for premenopausal women with ER positive breast cancer and for risk reduction in premenopausal women who are at high risk for developing breast cancer. The risk of endometrial cancer and thromboembolic disorders during tamoxifen therapy is not elevated in premenopausal women. It is important to note that aromatase inhibitors or raloxifene should not be used in premenopausal women. Raloxifene is used to prevent osteoporosis in postmenopausal women and, unlike tamoxifen, does not increase the risk of endometrial cancer. However, raloxifene does reduce breast cancer risk by 50-70% in both low risk and high risk postmenopausal women. Comparisons of raloxifene with tamoxifen show equal efficacy as a chemopreventive for breast cancer but there is a reduction in thromboembolic disorders, fewer endometrial cancers, hysterectomies, cataracts and cataract surgeries in women taking raloxifene. Overall, SERMs continue to fulfill their promise as appropriate medicines that target specific populations for the treatment and prevention of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.